Literature DB >> 33271108

Tumour mutational burden in treatment-resistant tumours.

Wei Nie1, Jie Qian2, Bo Zhang1, Hua Zhong1, Baohui Han3.   

Abstract

Entities:  

Year:  2020        PMID： 33271108     DOI： 10.1016/S1470-2045(20)30617-3

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  2 in total

1.  Comutations in DDR Pathways Predict Atezolizumab Response in Non-Small Cell Lung Cancer Patients.

Authors:  Anning Xiong; Wei Nie; Yan Zhou; Changhui Li; Kai Gu; Ding Zhang; Shiqing Chen; Fengcai Wen; Hua Zhong; Baohui Han; Xueyan Zhang
Journal:  Front Immunol       Date:  2021-09-24       Impact factor: 7.561

2.  TP53 Mutation Status and Biopsy Lesion Type Determine the Immunotherapeutic Stratification in Non-Small-Cell Lung Cancer.

Authors:  Jun Lu; Runbo Zhong; Yuqing Lou; Minjuan Hu; Zhengyu Yang; Yanan Wang; Ya Chen; Benkun Zou; Wei Zhang; Huimin Wang; Baohui Han
Journal:  Front Immunol       Date:  2021-09-17       Impact factor: 7.561
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.